Palmitoylethanolamide
Tier C — Watch / tradePalmitoylethanolamide
Targets：CB, PPARα
Brand：CannAmide
Indications (approved)：Atopic dermatitis, Chronic pain, Mania, Major depressive disorder, Opioid dependence, 肥大细胞增生症, Bone injury, 胫骨骨折
Regional status
Synthetic routes & intermediates1 routes
Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.
Frequently asked questions
What are the approved indications of Palmitoylethanolamide?
Approved indications include: Atopic dermatitis, Chronic pain, Mania, Major depressive disorder, Opioid dependence, 肥大细胞增生症, Bone injury, 胫骨骨折.
When does the Palmitoylethanolamide patent expire?
No public expiry year is available for Palmitoylethanolamide yet; this page updates once verified.
How many synthesis routes are recorded for Palmitoylethanolamide?
1 synthesis routes are recorded; the shortest is 1 steps with 95.1 g (Palmitoylethanolamide) total yield. Intermediates in each route carry codes and CAS numbers.
Where can I buy Palmitoylethanolamide intermediates?
All intermediates in Palmitoylethanolamide routes have CAS profiles — you can submit an RFQ per CAS and it enters the Unibest matching pool.
How do I get a quote for Palmitoylethanolamide intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-06